Secondary Lower‐Body Sarcomas in Cervical Cancer Survivors Following Surgery, Radiotherapy, or Both: A Population‐Based Study
Cancer Science · 2026
DOI: 10.1111/cas.70229 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2026. Verfasst von Toshiki Ikawa und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Control Center, Osaka International Cancer Institute, Osaka, Japan. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Sarcoma, Cancer Survivors, Neoplasms, Second Primary. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Secondary sarcomas in cervical cancer survivors are understudied. We investigated the incidence and subtypes of secondary sarcomas by treatment modalities, the prognosis of secondary sarcomas, and whether surgery plus radiotherapy increases angiosarcoma incidence. This population‐based retrospective cohort study analyzed Osaka Cancer Registry data on women aged 20–84 years diagnosed with cervical cancer (1980–2015), treated with surgery, radiotherapy, or both. Patients with distant metastases, survival time < 1 year, or missing data were excluded. We included 7591 patients with invasive cancer treated with surgery, 3882 with radiotherapy, and 4090 with surgery plus radiotherapy and 13,205 with carcinoma in situ treated with surgery. We assessed the first lower‐body sarcoma occurrence ≥ 1 year post‐diagnosis. Sarcomas developed in 6 patients treated with surgery (0 angiosarcomas), 10 with radiotherapy (1 angiosarcoma), and 19 with surgery plus radiotherapy (9 angiosarcomas). At 10 years, the cumulative incidence was 0.083% (95% confidence interval [CI], 0.024%–0.24%) for radiotherapy and 0.21% (95% CI, 0.10%–0.41%) for surgery plus radiotherapy, higher than that for surgery (invasive, 0.013%; in situ, 0.028%) ( p < 0.001). Angiosarcoma incidence was higher with surgery plus radiotherapy (0.080%; 95% CI, 0.023%–0.23%) than with radiotherapy (0.028%; 95% CI, 0.003%–0.16%) ( p = 0.029). Among patients diagnosed with sarcoma after radiotherapy or surgery plus radiotherapy, the 1‐year overall survival rate was 33.3% (95% CI, 19.6%–56.8%). Radiotherapy, alone or combined with surgery, increased secondary lower‐body sarcoma incidence compared with surgery. To our knowledge, this is the first population‐based study to suggest that surgery plus radiotherapy is associated with angiosarcoma in cervical cancer survivors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cancer Control Center, Osaka International Cancer Institute, Osaka, Japan.
- Department of Radiation Oncology, Osaka International Cancer Institute, Osaka, Japan.
- Department of Diagnostic Pathology and Cytology, Osaka International Cancer Institute, Osaka, Japan.
ORCID-Profile: Toshiki Ikawa, Kayo Nakata, Toshitaka Morishima, Yoshihiro Kuwabara, Mizuki Shimadzu Kato
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Ikawa, T., Nakata, K., Morishima, T., Yoshida, K. I., Kuwabara, Y., Kato, M. S., Iwaki, Y., Kanayama, N., Morimoto, M., Konishi, K., & Miyashiro, I. (2026). Secondary Lower‐Body Sarcomas in Cervical Cancer Survivors Following Surgery, Radiotherapy, or Both: A Population‐Based Study. Cancer Science. https://doi.org/10.1111/cas.70229
Vancouver
Ikawa T, Nakata K, Morishima T, Yoshida KI, Kuwabara Y, Kato MS, et al. Secondary Lower‐Body Sarcomas in Cervical Cancer Survivors Following Surgery, Radiotherapy, or Both: A Population‐Based Study. Cancer Science. 2026. doi:10.1111/cas.70229
BibTeX
@article{Ikawa2026,
author = {Ikawa, Toshiki and Nakata, Kayo and Morishima, Toshitaka and Yoshida, Ken-Ichi and Kuwabara, Yoshihiro and Kato, Mizuki Shimadzu and Iwaki, Yoko and Kanayama, Naoyuki and Morimoto, Masahiro and Konishi, Koji and Miyashiro, Isao},
title = {Secondary Lower‐Body Sarcomas in Cervical Cancer Survivors Following Surgery, Radiotherapy, or Both: A Population‐Based Study},
journal = {Cancer Science},
year = {2026},
doi = {10.1111/cas.70229}
}
EUVIMED